Li-Chun Lu

6PUBLICATIONS
26CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Dec 10, 2025
Expression of Poliovirus Receptor, the Ligand of TIGIT, Associated With Immune-Cold Tumor Microenvironment in Hepatocellular Carcinoma.

Li-Chun Lu, Yi-Hsuan Lee, Yu-Yun Shao

|Aug 18, 2025
PolyIC as an adjuvant outperforms anti-VEGF in combination with anti-PD-L1 therapy in mouse liver tumor models.

Yichun Ji, Li-Chun Lu, Hao Zhuang

|Aug 28, 2024
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.

Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas

|Aug 17, 2021
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance.

Yulei Wang, Li-Chun Lu, Yinghui Guan

|Aug 02, 2021
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma.

Ying-Chun Shen, Pei-Chang Lee, Yu-Lun Kuo

|Aug 11, 2019
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.

Yu-Yun Shao, Tsung-Hao Liu, Chiun Hsu

Pageof 1

Frequent Collaborators

2 joint publications

Yu-Yun Shao

2 joint publications

Tsung-Hao Liu

2 joint publications

Ann-Lii Cheng

2 joint publications

Chih-Hung Hsu